Diagnostic Histopathology最新文献_第8页

Preinvasive neoplasia of the gallbladder: flat and tumoral dysplasia 胆囊浸润前肿瘤：扁平和肿瘤性发育不良

Diagnostic Histopathology Pub Date : 2024-02-07 DOI: 10.1016/j.mpdhp.2024.01.005

Gavin Baker, Paul Kelly

{"title":"Preinvasive neoplasia of the gallbladder: flat and tumoral dysplasia","authors":"Gavin Baker, Paul Kelly","doi":"10.1016/j.mpdhp.2024.01.005","DOIUrl":"10.1016/j.mpdhp.2024.01.005","url":null,"abstract":"<div>Gallbladders are one of the most commonly encountered specimens in routine histopathology. While the usual diagnoses of cholelithiasis and cholecystitis are relatively straightforward, the evaluation of neoplastic changes in the gallbladder can be challenging. Non-invasive neoplasia in the gallbladder can be broadly categorised into flat or non-tumoral dysplasia and tumoral dysplasia, the latter mainly incorporating intracholecystic papillary neoplasms, akin to lesions seen within the bile ducts and pancreas. Flat dysplasia can be particularly difficult to diagnose due to morphological overlaps with reactive atypia, compounded by the common presence of inflammatory changes in cholecystectomy specimens. Tumoral dysplasia, while more easily recognisable, can be problematic due to the different, clinically relevant subtypes that exist. These display variable associations with invasive malignancy and the morphological differences between these lesions can be subtle. This review provides an overview of the key features of flat and tumoral dysplasia in the gallbladder, an approach to handling such cases, and some insights into the main diagnostic challenges that may be faced by general histopathologists when a neoplastic diagnosis is being considered.</div>","PeriodicalId":39961,"journal":{"name":"Diagnostic Histopathology","volume":"30 4","pages":"Pages 252-263"},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139822398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Histopathological risk stratification of pT1 colorectal cancer: novel insights into established risk factors pT1 结直肠癌组织病理学风险分层：对既定风险因素的新见解

Diagnostic Histopathology Pub Date : 2024-02-06 DOI: 10.1016/j.mpdhp.2024.01.007

Lisa van der Schee, Miangela M. Laclé

{"title":"Histopathological risk stratification of pT1 colorectal cancer: novel insights into established risk factors","authors":"Lisa van der Schee, Miangela M. Laclé","doi":"10.1016/j.mpdhp.2024.01.007","DOIUrl":"10.1016/j.mpdhp.2024.01.007","url":null,"abstract":"<div>The proportion of submucosal invasive (pT1) colorectal cancer (CRC) diagnoses has increased substantially since the introduction of CRC screening programmes. A distinct attribute of pT1 CRCs is that they can be potentially cured through local excision. With advancements in endoscopic or minimally invasive surgical resection techniques, local excision has become the primary treatment modality for the majority of these malignant polyps. After local excision, the decision regarding the need for additional surgical intervention is primarily based on the presence of histopathological risk factors for lymph node metastasis (LNM). Because of the implications for the patient, careful evaluation of these risk factors by pathologists is of great importance. In recent years, lots of attention has been paid to improve the histopathological risk classification of pT1 CRCs. This review article aims to provide a comprehensive overview of the established risk features, address the challenges encountered during histopathological assessment, and explore potential future directions for the histopathological evaluation of pT1 CRCs.</div>","PeriodicalId":39961,"journal":{"name":"Diagnostic Histopathology","volume":"30 4","pages":"Pages 191-202"},"PeriodicalIF":0.0,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139892089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Colonisation or invasion: a diagnostic dilemma in a ‘benign’ gallbladder 定植还是入侵："良性 "胆囊的诊断难题

Diagnostic Histopathology Pub Date : 2024-02-05 DOI: 10.1016/j.mpdhp.2024.01.006

Daniel T. Field, Alan Stockman, Timothy J. Kendall

引用次数: 0

The morphomolecular features of cholangiocarcinoma in the personalised era 个性化时代胆管癌的形态分子特征

Diagnostic Histopathology Pub Date : 2024-02-04 DOI: 10.1016/j.mpdhp.2024.01.004

Daniel T. Field, Guido Carpino, Michail Doukas, Timothy J. Kendall

引用次数: 0

Invasive breast cancer reporting guidelines: ICCR, CAP, RCPath, RCPA datasets and future directions 浸润性乳腺癌报告指南：ICCR、CAP、RCPath、RCPA 数据集和未来方向

Diagnostic Histopathology Pub Date : 2024-02-01 DOI: 10.1016/j.mpdhp.2023.11.001

Natthawadee Laokulrath, Mihir Ananta Gudi, Rahul Deb, Ian O Ellis, Puay Hoon Tan

{"title":"Invasive breast cancer reporting guidelines: ICCR, CAP, RCPath, RCPA datasets and future directions","authors":"Natthawadee Laokulrath, Mihir Ananta Gudi, Rahul Deb, Ian O Ellis, Puay Hoon Tan","doi":"10.1016/j.mpdhp.2023.11.001","DOIUrl":"10.1016/j.mpdhp.2023.11.001","url":null,"abstract":"<div>Pathological characteristics are essential for breast cancer staging and treatment; hence, regional and country-based pathology reporting protocols have been produced to facilitate comprehensive reporting by pathologists. However, these guidelines can vary in reporting variables, terminology definition, methods of measurement/scoring, which may lead to discordant information for clinicians and disagreement among pathologists. To obviate this, the International Collaboration on Cancer Reporting (ICCR) has recently produced datasets for histological reporting of breast cancer to unify the reporting elements, facilitating international comparability. In this review, we focus on the invasive breast carcinoma reporting datasets with the aim of providing an overview of ICCR recommendations in comparison with those published by regional professional organizations (the Royal College of Pathologists of the United Kingdom (UK) (RCPath), the United States (US) College of American Pathologists (CAP), the Royal College of Pathologists of Australasia (RCPA)), including relevant evidence with practical tips on accurate reporting of breast cancer resection specimens. In addition, we discuss some divergent aspects and suggest future directions for a unified breast cancer pathology reporting framework.</div>","PeriodicalId":39961,"journal":{"name":"Diagnostic Histopathology","volume":"30 2","pages":"Pages 87-99"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139128634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practical approach to diagnosis of breast lesions with heterologous components 诊断具有异体成分的乳腺病变的实用方法

Diagnostic Histopathology Pub Date : 2024-02-01 DOI: 10.1016/j.mpdhp.2023.11.002

Abeer M Shaaban, Cecily Quinn, Emad Rakha

引用次数: 0

Review of immune checkpoint blockade and PD-L1 testing in breast cancer 乳腺癌免疫检查点阻断和 PD-L1 检测综述

Diagnostic Histopathology Pub Date : 2024-02-01 DOI: 10.1016/j.mpdhp.2023.12.001

Adelina Baltan, Simona Costache, Abeer M Shaaban , Corrado D'Arrigo

{"title":"Review of immune checkpoint blockade and PD-L1 testing in breast cancer","authors":"Adelina Baltan, Simona Costache, Abeer M Shaaban , Corrado D'Arrigo","doi":"10.1016/j.mpdhp.2023.12.001","DOIUrl":"10.1016/j.mpdhp.2023.12.001","url":null,"abstract":"<div>In the past two decades, several drugs have been developed to modulate the immune checkpoints. These modulators regulate, amongst others, the T-cell mediated immune response and may be involved in the escape from immune surveillance. Mounting evidence in several solid tumours points towards the effectiveness of immune checkpoint blockade (ICB) therapy used either as monotherapy or in combination with conventional chemotherapy. In breast cancer, ICB therapy is effective in the treatment of triple negative breast cancer (TNBC). Several PD-L1 companion diagnostic tests have been developed for the selection of patients more likely to benefit from this treatment. Currently, two PD-L1 assays are approved for clinical use in TNBC patients: the SP142 CDx for the use of atezolizumab and the 22C3 PharmDx for the use of pembrolizumab. This review provides the background of PD-L1 testing in breast cancer and discusses the analytical performance of these tests, their scoring algorithms and inter-observer concordance and outlines best practice, including tissue selection, tools for interpretation and use of controls.</div>","PeriodicalId":39961,"journal":{"name":"Diagnostic Histopathology","volume":"30 2","pages":"Pages 110-122"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139454983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of B coding of breast core biopsy categorisation and management implications 乳腺核芯活检 B 编码分类及管理影响概述

Diagnostic Histopathology Pub Date : 2024-02-01 DOI: 10.1016/j.mpdhp.2023.11.004

Andrew HS Lee, Sarah E Pinder

{"title":"An overview of B coding of breast core biopsy categorisation and management implications","authors":"Andrew HS Lee, Sarah E Pinder","doi":"10.1016/j.mpdhp.2023.11.004","DOIUrl":"10.1016/j.mpdhp.2023.11.004","url":null,"abstract":"<div>The United Kingdom National Health Service Breast Screening Programme proposes five B categories for reporting breast screening needle core biopsies. The system is also recommended for symptomatic patients and diagnostic vacuum-assisted biopsies. Usually over 90% of biopsies are categorised as normal (B1), benign (B2) or malignant (B5). B3 is a heterogeneous group including atypical intraductal proliferations, classical lobular neoplasia, papillary lesions, radial scars, cellular fibroepithelial lesions and some rarer lesions. It is important to comment on the presence of epithelial atypia in B3 lesions as the risk of malignancy in the excision specimen is higher if atypia is present. Recent United Kingdom guidelines propose more thorough sampling with vacuum-assisted biopsy as an alternative to diagnostic surgical excision for some B3 lesions. B4 is used for lesions suspicious of malignancy. Further investigation is usually needed for B4 lesions. B5 is subdivided into B5a for DCIS and pleomorphic LCIS, B5b for invasive carcinoma, lymphoma, sarcoma, malignant phyllodes tumour and metastases from extramammary malignancies, and B5c for carcinomas that cannot be classified as in situ or invasive. The biopsy result must be discussed at the multidisciplinary meeting in combination with the clinical and radiological findings (the triple approach) to guide patient management.</div>","PeriodicalId":39961,"journal":{"name":"Diagnostic Histopathology","volume":"30 2","pages":"Pages 132-140"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138610532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An interesting case of tall cell carcinoma of the breast with reverse polarity 一个有趣的反极性乳腺高细胞癌病例

Diagnostic Histopathology Pub Date : 2024-02-01 DOI: 10.1016/j.mpdhp.2023.11.005

Caroline Cartlidge, Eldo Thomas Verghese

引用次数: 0

Pitfalls and mass-forming mimics of pancreatic cancer 胰腺癌的隐患和肿块形成模拟物

Diagnostic Histopathology Pub Date : 2024-02-01 DOI: 10.1016/j.mpdhp.2024.01.003

Yoh Zen

{"title":"Pitfalls and mass-forming mimics of pancreatic cancer","authors":"Yoh Zen","doi":"10.1016/j.mpdhp.2024.01.003","DOIUrl":"10.1016/j.mpdhp.2024.01.003","url":null,"abstract":"<div>The diagnostic pathway of pancreatic lesions has changed since endoscopic ultrasound-guided biopsies were introduced. The tissue diagnosis of pancreatic ductal adenocarcinoma (PDAC) used to be made by cytology or surgical specimens, while pancreatic biopsies currently contribute to a pretreatment diagnosis in >80 % of cases. Pathologists need to assess subtle changes in biopsy specimens, in order to avoid over- and under-diagnosis of PDAC. The lack of stromal reaction does not exclude the possibility of PDAC, while abnormal distribution of the ducts and a mild but sufficient degree of nuclear atypia are diagnostic clues for well differentiated PDAC. It is also important to be aware of distinct types of pancreatitis that potentially presents with a tumour. IgG4-related autoimmune pancreatitis (type 1 AIP) is widely recognised as a mimic of PDAC. Other forms of mass-forming pancreatitis include type 2 AIP (IgG4-unrelated), follicular pancreatitis, groove pancreatitis and acute interstitial pancreatitis. Most of those conditions lack serological diagnostic markers; therefore, the histology plays a central role in the diagnosis.</div>","PeriodicalId":39961,"journal":{"name":"Diagnostic Histopathology","volume":"30 4","pages":"Pages 227-236"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139684528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0